Fundz

GSK acquires SiranBio for $1B in weight-loss strategy

PUBLIC · GSKMay 07, 2026

Acquiring Company

GSK plc

Acquired Company

Siran Biotechnology

ChinaManufacturingBiotechnologyHealth CarePharmaceutical

Description

GSK has acquired Siran Biotechnology for over $1 billion to enhance its investigational siRNA therapy for metabolic diseases. The deal includes access to SiranBio's SA030, targeting the ALK7 receptor, which has potential benefits for weight management. This acquisition aligns with GSK's strategy to address health issues related to obesity and metabolism.

Quick answer

GSK plc is acquiring Siran Biotechnology for $1 billion, announced May 7, 2026.

How much did GSK plc pay for Siran Biotechnology?
The reported deal value is $1 billion.
What does GSK plc do?
GSK plc is a global healthcare company that researches and develops innovative pharmaceutical products, including vaccines.
Where are GSK plc and Siran Biotechnology based?
Siran Biotechnology is based in China.
Who are the decision-makers at GSK plc?
Fundz holds 4 contacts at GSK plc. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Other recent acquisitions in Pharmaceutical and Manufacturing

Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.

Who to call at GSK plc, and when

When GSK plc changes hands, the new owners review vendors, systems and leadership. That is when the door opens.

  • An alert the day GSK plc raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at GSK plc, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at GSK plc. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

GSK plc

Location

79 New Oxford Street

About

GSK plc is a global healthcare company that researches and develops innovative pharmaceutical products, including vaccines. The company is dedicated to improving the quality of human life by enabling people to do more, feel better, and live longer. GSK focuses on a range of health needs, including respiratory diseases, and has a commitment to develop life-saving medications and preventative treatments.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment GSK plc makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Luke
Likely contact at this company
••••••••@••••••••

See Luke's verified email →

Anshuman
Senior decision-maker at this company
••••••••@••••••••

See Anshuman's verified email →

Vineet
Senior decision-maker at this company
••••••••@••••••••

See Vineet's verified email →

Saurabh
Senior decision-maker at this company
••••••••@••••••••

See Saurabh's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for GSK plc's next move

Learn about Strategic plan

Frequently asked

Who acquired Siran Biotechnology?

Siran Biotechnology was acquired by GSK plc. The deal was reported on May 7, 2026. GSK plc is a global healthcare company that researches and develops innovative pharmaceutical products, including vaccines. GSK plc is publicly traded (GSK) and operates in Manufacturing.

When did GSK plc acquire Siran Biotechnology?

GSK plc's acquisition of Siran Biotechnology was reported on May 7, 2026. GSK has acquired Siran Biotechnology for over $1 billion to enhance its investigational siRNA therapy for metabolic diseases. The deal includes access to SiranBio's SA030, targeting the ALK7 receptor, which has potential benefits for weight management. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Siran Biotechnology do?

Siran Biotechnology is a company specializing in RNA development, specifically focused on siRNA therapies for various metabolic diseases. The company is dedicated to advancing innovative solutions targeting cardiovascular and metabolic health issues. It is privately held, and is based in China.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.